Abstract: Disclosed are processes for making cyclohexanone from a feed mixture comprising cyclohexylbenzene, cyclohexanone, phenol, 3-cylclohexenone and optionally 2-cyclohexenone, comprising feeding the feed mixture to a first distillation column and hydrogenating a fraction from the first distillation column in a hydrogenation reactor separate from the first distillation in the presence of a hydrogenation catalyst under hydrogenation conditions. A cyclohexanone-rich upper effluent comprising 3-cyclohexenone and 2-cyclohexenone at low concentrations can be obtained from the first distillation column.

Abstract: In an embodiment a method of purifying acetone, comprises directing a feed stream comprising greater than or equal to 97 wt % of acetone and 100 to 1,000 ppm of methanol to a separation column, both based on a total weight of the feed stream; separating the feed stream in the separation column that is operating at a pressure greater than or equal to 1 bar into an overhead stream and a purified acetone stream comprising less than or equal to 50 ppm of methanol based on a total weight of the purified acetone stream; and directing at least 80 wt % of the overhead stream into the separation column as a reconstituted stream and purging 1 to 20 wt % of the overhead stream as a purge stream.

Abstract: A method for producing an aqueous equilibrium peroxylactic acid solution by reaction mixing lactic acid, hydrogen peroxide, water, one or more optional acid catalysts and one or more optional sequestering agents in a vessel over a period of time while maintaining the temperature of the solution at a temperature below about 100° C. The aqueous equilibrium peroxylactic acid solution can be used for reducing the bacterial count on a protein food product during processing.

Abstract: Disclosed is a method for production of a methyl ester based formulation. The method involves: providing a feedstock containing about 1% to about 100% canola oil; removing water from the feedstock; heating the feedstock to at least about 60° C.; mixing a solution of about 90% to about 100% (v/v) methanol and a strong base with the heated feedstock to produce a mixture containing methyl ester; and allowing the mixture containing methyl ester to rest for at least one hour. The composition of the methanol and strong base solution being calculated based on the free fatty acid content of the feedstock. The methyl ester based formulations produced by the method can be used as ecofriendly penetrating oils, lubricating oils, machining fluid or releasing agents.

Abstract: The invention provides processes and materials for the efficient and cost-effective functionalization of alkanes, such as methane from natural gas, to provide esters, alcohols, and other compounds. The method can be used to produce liquid fuels such as methanol from a natural gas methane-containing feedstock. The soft oxidizing electrophile, a compound of a main group, post-transitional element such as Tl, Pb, Bi, and I, that reacts to activate the alkane C—H bond can be regenerated using inexpensive regenerants such as hydrogen peroxide, oxygen, halogens, nitric acid, etc. Main group compounds useful for carrying out this reaction includes haloacetate salts of metals having a pair of available oxidation states, such as Tl, Pb, Bi, and I.

Abstract: A method for preparing methyl methacrylate from methacrolein and methanol. The method comprises contacting in a tubular reactor having at least four zones a mixture comprising methacrolein, methanol, oxygen and a base with a catalyst bed of heterogeneous catalyst comprising a support and a noble metal, wherein reaction zones comprising catalyst beds alternate with mixing zones not comprising catalyst beds.

Abstract: The disclosure provides a synthesis method of 2,4,6-trifluorobenzylamine, belonging to the technical field of chemical synthesis. The synthesis method is characterized by comprising the following steps: (1) allowing pentachlorobenzonitrile as a raw material to undergo fluoridation reaction with a fluoridation agent based on 2,4,6-trifluoro-3,5-dichlorobenzonitrile as a solvent to obtain 2,4,6-trifluoro-3,5-dichlorobenzonitrile; (2) hydrogenating the obtained 2,4,6-trifluoro-3,5-dichlorobenzonitrile with hydrogen in the presence of organic carboxylic acid, based, on palladium carbon as a catalyst to obtain 2,4,6-trifluoro-3,5-dichlorobenzylamine; and (3) hydrogenating the obtained 2,4,6-trifluoro-3,5-dichlorobenzylamine with hydrogen in a solvent in the presence of a catalyst to obtain 2,4,6-trifluorobenzylamine.

Abstract: Various polymorphic forms of RAD1901-2HCl, including three crystalline and amorphous forms, are prepared and characterized. Uses of the various polymorphic forms of RAD1901-2HCl for cancer treatment are also disclosed.

Abstract: Disclosed are methods for preparing compounds of Formula 1 and 1A. The first method utilizes a benzyl carbamate amine protecting group and an intermediate of Formula 4. The second method utilizes a tert-butyl carbamate amine protecting group and an intermediate of Formula 7. The third method utilizes a dibenzyl amine protecting group. Also disclosed is a compound, phenylmethyl N-[2-oxo-2-[(2,2,2-trifluoroethyl)amino]ethyl]carbamate (a compound of Formula 4). Further disclosed is a method for preparing a compound of Formula 14 from a compound of Formula 15 and a compound of Formula 1 or 1A.

Abstract: Disclosed are compositions and methods for preventing or reducing polymer formation and polymer deposition in equipment used in petrochemical processes. An antifoulant composition includes a combination of one or more antioxidants; one or more antipolymerants; one or more dispersants; and one or more solvents. A method of preventing or reducing fouling of process equipment used in an industrial process is also described. The method includes introducing into the process equipment an antifoulant composition, the antifoulant composition comprising a combination of one or more antioxidants; one or more antipolymerants; one or more dispersants; and one or more solvents.

Abstract: Some novel compounds are provided in this disclosure. These novel compounds have potential SHP-1 agonist activity for being used in treating cancer.

Abstract: Sulfate and sulfonate derivatives of unsaturated fatty alcohols, processes for making them, and methods of using them are disclosed. In one aspect, a monounsaturated fatty alcohol composition is made by reducing a metathesis-derived monounsaturated alkyl ester. The fatty alcohol composition is then converted to a sulfate or sulfonate derivative by one or more of alkoxylation, sulfation, sulfonation, and sulfitation. Of particular interest are the sulfate and ether sulfate derivatives.

Abstract: A process for preparing diaryl sulfones, such as 4,4?-dichlorodiphenylsulfone is disclosed. The process comprises contacting an aryl compound with sulfur trioxide to provide a benzene sulfonic acid. The benzene sulfonic acid is coupled to additional aryl compound in the presence of a catalyst. During the coupling step, the additional aryl compound is continuously added while water is removed.

Abstract: The invention relates to ceramide dimers in which the amino alcohols are linked together by amide bonds via a dicarboxylic acid. The dicarboxylic acids have at least one sulfur atom in the chain. The invention also relates to a method for producing the ceramide dimers. The ceramide dimers are used as active ingredients to stabilize the skin barrier in cosmetic and pharmaceutical preparations.

Abstract: The invention relates to new compounds with low cytotoxicity for blocking ubiquitination-proteasome system in diseases. Accordingly, these compounds can be used in treatment of treating disorders including, but not limited to, cancers, neurodegenerative diseases, inflammatory disorders and autoimmune disorders and metabolic disorders.

Abstract: A process for providing phycocyanin from a blue-green algae biomass comprising the steps of forming a slurry of blue-green algae by mechanically mixing the blue-green algae in water to break up filaments of the biomass and incubating the macerated slurry in a container with at least a 1% flocculating agent for a period of time sufficient to separate a blue extract from the slurry. The blue extract is separated and filtered through a filter to obtain a blue filtrate and the blue filtrate is mixed in a container with an ammonium sulfate precipitate for a suitable period of time to obtain supernatant protein separation. The supernatant is syphoned from the container and the settled participate is centrifuged at a rpm ranging from about 3500 rpm to about 4500 rpm for a sufficient time to produce phycocyanin precipitate.

Abstract: Dual function compounds are provided that may be inhibitors of histone deacetylase (HDAC) and activators of ataxia telangiectasia mutated (ATM). Pharmaceutical compositions and methods of use are also provided that utilize such compounds.

Abstract: The invention relates to a compound of formula (I), characterised by the characteristic signals in the X-ray diffraction powder pattern measured with Cu Kalpha radiation (0.154 nm) at a 2-theta angle of 15.0 and 22.7 with a high intensity, and of 5.0, 11.3, 18.9, 20.8, 21.6 and 23.6 with a medium intensity, as well as to a method for producing the compound of formula (I) by reacting at least one isophthalic acid diester of formula (II) where R1 and R2 are the same or different and stand for an aliphatic group, with two equivalents 4-amino-2,2,6,6-tetramethylpiperidine, in the presence of at least one catalyst from the group of metal alcoholates and at a reaction temperature of between 50 and 150° C.

Abstract: The present disclosure provides methods for enantioselective synthesis of cyclic and acyclic ?-quaternary carboxylic acid derivatives via nickel-catalyzed allylic alkylation.

Abstract: The present invention relates to new pharmaceutical agents, and to their use in the treatment of proliferative diseases, such as cancer (in particular, brain cancer).

Abstract: The present invention provides compounds for the treatment of a bacterial infection. Additionally, the present invention provides compositions and methods for using these compounds and compositions in the treatment of a bacterial infection in a subject.

Abstract: The present invention relates (i) to a process for the preparation of quinolin-2-yl-phenylamine derivatives of formula (I) without a metal catalyst, and (ii) to soluble mineral acid or sulfonic acid salts of (8-chloro-quinolin-2-yl)-(4-trifluoromethoxyphenyl)-amine.

Abstract: Compounds of Formula I or pharmaceutically acceptable salts or esters thereof capable of binding to and modulating the activity of a stimulator of interferon genes (STING) protein are provided. Methods involving compounds of Formula I as effective modulators of STING are also provided.

Abstract: Disclosed herein are DKP microcrystals made by an improved method where they do not irreversibly self-assemble into microparticles. The microcrystals can be dispersed by atomization and re-formed by spray drying into particles having spherical shell morphology. Active agents and excipients can be incorporated into the particles by spray drying a solution containing the components to be incorporated into microcrystalline diketopiperazine particles. In particular, the microcrystalline particle compositions are suitable for pulmonary drug delivery of one or more peptides, proteins, nucleic acids and/or small organic molecules.

Abstract: A compound for treating a protein kinase-related disease or disorder having a structure of formula (I) wherein L is NR8 or O; R1, R2, R3, R4, R5, R6 and R7 are defined herein. Compounds of formula (I) are useful for inhibition of protein kinases. Methods of using compounds of formula (I), stereoisomers, tautomers and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.

Abstract: The present invention relates to compounds having dual pharmacological activity towards both the sigma (?) receptor, and the ?-opiod receptor and more particularly to piperazine compounds having this pharmacological activity, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use in therapy, in particular for the treatment of pain.

Abstract: The present specification provides a hetero-cyclic compound and an organic light emitting device comprising the same.

Abstract: Provided are crystal forms A, B, D, E, F, G and H of valsartan disodium salt and a preparation method therefor.

Abstract: The invention provides certain bicylic heterocyclic compounds of the Formula (I) or pharmaceutically acceptable salts thereof, wherein X1, X2, R1, R2, R3, R4, and Cy are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds of the Formula (I) or pharmaceutically acceptable salts thereof, and methods of using the compounds of the Formula (I) or pharmaceutically acceptable salts thereof or pharmaceutical compositions comprising the same for treating diseases or conditions mediated by RORgammaT.

Abstract: A method to detect the presence or amount of at least one molecule in a sample which employs a derivative of luciferin or a derivative of a fluorophore is provided. Compounds and compositions for carrying out the methods of the invention are also provided.

Abstract: The invention provides compounds having the general formula I: and pharmaceutically acceptable salts thereof, wherein the variables R1, R2, R3, R4, subscipt m and n, have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.

Abstract: Disclosed is a method for preparing a formamide compound, the method uses carbon dioxide, hydrogen and an amine compound as raw materials and a transition metal complex as a catalyst, and the reaction is carried out in an organic solvent or in the absence of a solvent to form a formamide compound. The method of the present invention is an effective method of chemical utilization of carbon dioxide, which has the advantages of high reaction efficiency, a good selectivity, mild conditions, economic and environmental protection, being simple and convenient to operate and the like, and has a good popularization and application prospect.

Abstract: Plasticizers are purified by contact with a coalescing filter to effect removal of ions, metals, monohydric alcohols, and polyhydric alcohols. The resulting purified plasticizer compositions are suitable for use in PVC due to their low levels of impurities that reduce PVC utility.

Abstract: An integrated process is useful for producing 2,5-furandicarboxylic acid (FDCA) and/or a derivative thereof from a six-carbon sugar-containing feed. The process includes a) dehydrating a feed containing a six-carbon sugar unit, in the presence of a bromine source and of a solvent, to generate an oxidation feed that contains at least one of 5-hydroxymethylfurfural (HMF) and/or a derivative or derivatives of HMF in the solvent, together with at least one bromine containing species; b) contacting the oxidation feed from step (a) with a metal catalyst and with an oxygen source under oxidation conditions to produce an oxidation product mixture of at least FDCA and/or a derivative thereof, the solvent, and a residual catalyst: c) purifying and separating the mixture obtained in step (b) to obtain FDCA and/or a derivative thereof and the solvent; and d) recycling at least a portion of the solvent obtained in step (c) to step (a).

Abstract: Disclosed herein are novel compounds and uses thereof. The present compounds may suppress the activity of farnesyl transferase and thus, may act as modulators of immune cells; therefor, they are useful for the development of a medicament for treating diseases that are associated with or caused by excessive levels of farnesyl transferase or immune response. Also disclosed herein are pharmaceutical compositions containing the present compounds.

Abstract: Provided herein are methods for making an alpha-tocotrienol enriched tocol mixture, such as from a plant or plant-derived material. Also provided herein are simulated moving bed purification methods for tocotrienol compounds such as alpha tocotrienol.

Abstract: A compound represented by the following formula (1): wherein each X independently represents an oxygen atom or a sulfur atom, or non-crosslinking, R1 represents a single bond or a 2n-valent group having 1 to 30 carbon atoms, the group may have an alicyclic hydrocarbon group, a double bond, a hetero atom, or an aryl group having 6 to 30 carbon atoms, each R2 independently represents a straight, branched or cyclic alkyl group having 1 to 10 carbon atoms, an aryl group having 6 to 10 carbon atoms, an alkenyl group having 2 to 10 carbon atoms, an alkoxy group having 1 to 30 carbon atoms, an aryloxy group having 6 to 30 carbon atoms, or a hydroxyl group, in which at least one R2 represents an alkoxy group having 1 to 30 carbon atoms or an aryloxy group having 6 to 30 carbon atoms, each m is independently an integer of 1 to 6, each p is independently 0 or 1, and n is an integer of 1 to 4.

Abstract: The present invention relates to a process for preparing fluorescein quinoid form of Formula (I): Furthermore, the present invention relates to a new solid fluorescein form and a process for the preparation thereof. The present invention also relates to the use of said new solid fluorescein form in the synthesis of fluorescein quinoid form.

Abstract: The present invention relates to a process for synthesizing lactide, comprising the steps of: providing one or more components to at least one reactor, the one or more components comprising lactic acid and a solvent; converting at least part of the lactic acid into lactide and water; recovering at least part of the lactide; and recovering at least part of the water; wherein the step of converting at least part of the lactic acid into lactide and water is performed in one step; and wherein the step of recovering at least part of the water comprises a decantation step, preferably with the proviso that the step of recovering at least part of the water does not comprise an azeotropic distillation step.

Abstract: New adipate-type compounds suitable as an intermediate in organic chemistry, a platform chemical for the production of other chemicals, and as a monomer and a co-monomer useful for the preparation of polymers and co-polymers. Also, a process of preparing the new adipate-type compounds from bio-based raw materials such as sugars.

Abstract: Provided herein are processes for the preparation of heteroaryl carboxylic acids.

Abstract: The present invention relates to piperidine or piperazine linked imidazole and triazole derivatives, compositions comprising said compounds, alone or in combination with other drugs, and methods of using the compounds for improving the pharmacokinetics of a drug. The compounds of the invention are useful in human and veterinary medicine for inhibiting CYP3A4 and for improving the pharmacokinetics of a therapeutic compound that is metabolized by CYP3A4.

Abstract: The present invention relates to a process for preparing compound 1 that is useful as an antifungal agent. In particular, the invention seeks to provide new methodology for preparing compound 1 and substituted derivatives thereof.

Abstract: Provided herein are small molecule inhibitors for the targeting or IRE1 protein family members. Binding may be direct or indirect. Further provided herein are methods of using IRE1 small molecule inhibitors for use in treating or ameliorating cancer in a subject. Moreover, IRE1 small molecule inhibitors described herein are for the treatment of cancer, where the cancer is a solid or hematologic cancer.

Abstract: A compound of formula (Ia), (Ib) or (Ic) wherein: n is 1 or 2; RN is H or Me; R1 is optionally one or more halo or methyl groups; R2a and R2b are independently selected from the group consisting of: (i) F; (ii) H; (iii) Me; and (iv) CH2OH; R2c and R2d (if present) are independently selected from the group consisting of: (i) F; (ii) H; (iii) Me; and (iv) CH2OH; R3a and R3b are independently selected from H and Me; R4a is selected from OH, —NH2, —C(?O)NH2, and —CH2OH; R4b is either H or Me; R5 is either H or Me; A is either (i), where R6a is ether; or (ii), where X is selected from CH2, NH and O, one of R7a and R7b is selected from CI and ethoxy and the other of R7a and R7b is H.

Abstract: The present invention relates to indoline-based compounds that inhibit Rho-associated protein kinase (ROCK) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of inhibiting ROCK activity and methods for treating, for example cerebral cavernous malformation syndrome (CCM) and cardiovascular diseases using the compounds and pharmaceutical compositions of the present invention.

Abstract: The present disclosure generally relates to compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical compositions comprising at least one compound according to the disclosure that are useful for the treatment of various diseases, including cancer and infectious diseases.

Abstract: Disclosed are compounds having formulae I and II or pharmaceutically acceptable salts or hydrates thereof, a preparation method thereof and pharmaceutical compositions thereof. The compounds having formulae I and II possesses an isocitrate dehydrogenase 2 (IDH2) inhibitory activity and are capable of treating IDH2 mutation-induced cancers.

Abstract: The present invention provides compounds of Formula (Ia) or (Ib): or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds are antagonists to ?V-containing integrins. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of ?V-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

Abstract: Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I): or a pharmaceutically acceptable salt, stereoisomer, isotopic form or prodrug thereof, wherein R1, R2a, R2b, R2c, R3a, R3b, R4a, R4b, R5, L1, L2, L3, E, m1, m2 and * are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also provided.